BioCentury | Mar 23, 2018
Clinical News

ObsEva's preterm labor candidate well tolerated in Phase I

...is a prostaglandin F2 alpha receptor (PGF2 alpha) antagonist. ObsEva S.A. (NASDAQ:OBSV), Geneva, Switzerland Product: OBE022 Business: Genitourinary Molecular target: Prostaglandin F2 alpha receptor (PGF2 alpha)...
BioCentury | Aug 22, 2016
Clinical News

OBE022: Phase I started

...female volunteers. ObsEva S.A. , Geneva, Switzerland Product: OBE022 Business: Genitourinary Molecular target: Prostaglandin F2 alpha receptor (PGF2 alpha) Description: Prostaglandin F2 alpha receptor (PGF2 alpha)...
BioCentury | Nov 24, 2015
Financial News

ObsEva raises CHF60M, strikes endometriosis deal

...ObsEva also intends to start a Phase I study in mid-2016 of OBE002 , its prostaglandin F2 alpha receptor (PGF2 alpha)...
Items per page:
1 - 3 of 3